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Abstract

This report used high-performance affinity microcolumns to
examine the changes in binding by sulfonylurea drugs to in
vivo glycated HSA that had been isolated from individual patients with diabetes. An immunoextraction approach was developed to isolate HSA and glycated HSA from clinical samples,
using only 20 μL of plasma or serum and 6–12 nmol of protein to prepare each affinity microcolumn. It was found that
the affinity microcolumns could be used in either frontal analysis or zonal elution studies, which typically required only 4–8
min per run. The microcolumns had good stability and allowed
data to be obtained for multiple drugs and experimental conditions over hundreds of sample application cycles. Both the
overall binding, as measured by frontal analysis, and site-specific interactions, as examined by zonal elution, showed
good agreement with previous data that had been obtained for in vitro glycated HSA with similar levels of modification.
It was also possible to directly compare the changes in site-specific binding that occurred between sulfonylurea drugs
or as the level of HSA glycation was varied. This method is not limited to clinical samples of glycated HSA but could be
adapted for work with other modified proteins of interest in personalized medicine.

P

ersonalized medicine holds great promise for improving
disease diagnosis and therapy through the customization
of treatment based on a patient’s specific needs. 1-3 Diabetes is
one disease for which this approach is of potential interest. 4-7
The number of diabetic patients has increased by 90% over the
last 20 years, with an estimated 26 million individuals in the
U.S. suffering from this disease. 4, 5
Some of the complications of diabetes are associated with
the nonenzymatic glycation of proteins. 8 Glycation begins
when a free amine group on a protein reacts with an aldehyde
group on a reducing sugar (e.g., glucose) to form a reversible
Schiff base, which can later rearrange to produce a more stable fructosamine residue, or Amadori product. 9-11 Numerous
studies have indicated that glycation can produce structural
and functional modifications in proteins with long half-lives
(e.g., collagen, lens crystalline, and hemoglobin). 12, 13 Recent
research has also examined the effects of glycation on human
serum albumin (HSA), the main protein in serum and an important binding agent for transporting many drugs and endogenous compounds in the circulatory system. 14-19
The binding of drugs to HSA usually occurs at Sudlow
sites I and II, which are located in subdomains IIA and IIIA

of this protein. 20 It has been suggested that the binding of
HSA to some drugs can be altered by glycation-related modifications that occur in the vicinity of Sudlow sites I and II. 16,
18 A group of drugs that may exhibit such changes are the sulfonylureas, which have been used to treat type II diabetes for
over 50 years. 21 These drugs are highly bound (i.e., 90–99%)
to serum proteins and particularly to HSA. 22 Displacement
or release of these drugs from serum proteins is known to
cause hypoglycemia, 23 while the presence of an effective dose
that is too low for the same drugs may result in elevated glucose levels.
In previous studies, high-performance affinity chromatography (HPAC) has been used to examine the interactions between several first- and second-generation sulfonylurea drugs
with normal and in vitro glycated HSA. 24-27 The use of HPAC
over conventional methods for monitoring drug–protein binding (e.g., ultrafiltration and equilibrium dialysis) has several
benefits, such as the high reproducibility of this method plus
its good precision and ease of automation. Other advantages
include the small sample requirements of HPAC and its ability to reuse the same protein preparation for hundreds of experiments. 28, 29
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In this report, HPAC will be explored for use in studying
drug interactions with in vivo glycated HSA that has been isolated from individuals known to have diabetes. Initial studies
will examine the use of immunoextraction columns for isolating in vivo glycated HSA from small amounts of samples obtained from patients and will combine this approach with recent developments in the preparation of affinity microcolumns
for drug–protein binding studies. 28, 30 The resulting affinity microcolumns will then be used to look at the overall binding of several sulfonylurea drugs to in vivo glycated HSA, as
will be studied by frontal analysis. The same columns will be
employed with zonal elution to detect any changes in binding
that might occur for the tested drugs at Sudlow sites I and II
upon the in vivo glycation of HSA in individual patients. The
results should provide information that can be used to better
understand these interactions and should lead to new analytical tools that can be employed in personalized medicine for patients with diabetes or other diseases.

Experimental Section

Materials and Reagents. The following solutes were
purchased from Sigma-Aldrich (St. Louis, MO): acetohexamide (99% pure), tolbutamide (99.8%), gliclazide (99.5%),
R-warfarin (>99%), and l-tryptophan (>99%). A commercial sample of serum made from male AB plasma was also obtained from Sigma-Aldrich (product H4522, lot 039K0728;
prescreened and found to be negative for HIV-1/HIV-2, hepatitis B and hepatitis C). The Nucleosil Si-300 (particle size, 7
μm; pore size, 300 Å) was from Macherey-Nagel (Düren, Germany). Reagents for the bicinchoninic acid (BCA) protein assay, as used for determining the protein content of the isolated
glycated HSA samples and chromatographic supports, were
from Pierce (Rockford, IL). The measurement of glycation levels was conducted by using a fructosamine assay kit from Diazyme Laboratories (San Diego, CA), as described previously. 25
The Vivapure anti-HSA resin was from Sartorius Stedim Biotech (Göttingen, Germany). All buffers and aqueous solutions
were prepared using water from a Nanopure system (Barnstead, Dubuque, IA) and were filtered using 0.2 μm GNWP nylon filters from Millipore (Billerica, MA).
Apparatus. The isolation of HSA and glycated HSA from
serum or plasma was performed using a 5702RH temperature-controlled centrifuge from Eppendorf (New York, NY)
and a fixed-angle centrifuge rotor from VWR (West Chester,
PA). The chromatographic experiments were carried out by using a Jasco 2000 HPLC system (Easton, MD) that contained
a DG-2080–53 three solvent degasser, two PU-2080 isocratic
pumps, an AS-2057 autosampler equipped with a 100 μL sample loop (operated in the partial loop injection mode), and a
UV-2075 absorbance detector. The columns were kept at 37 °C
by using a Jasco CO-2060 column oven. A Rheodyne Advantage PF six-port switching valve (Cotati, CA) was used for alternating the passage of drug and buffer solutions through the
columns during the frontal analysis studies. The system components were controlled by a Jasco LC-Net II/ADC system and
EZChrom Elite software v3.2.1 (Scientific Software, Pleasanton, CA). The breakthrough times for the frontal analysis data
and central peak moments for the zonal elution data were determined by using PeakFit 4.12 (SeaSolve Software, San Jose,
CA). Linear and nonlinear regression were conducted by utilizing DataFit 8.1.69 (Oakdale Engineering, PA).
Sample Pretreatment and Column Preparation.
Pre-existing EDTA plasma samples, acquired through veni-
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puncture and generated according to standard procedures for
work with whole blood (see Supporting Information), were obtained from deidentified patients known to have diabetes, as
provided by W. Clarke at the Johns Hopkins University School
of Medicine. The collection and provision of these samples was
performed with approval of the Johns Hopkins Institutional
Review Board. All of these samples were handled with appropriate precautions for materials that may contain bloodborne
pathogens. The level of hemoglobin A1c (HbA1c) was measured and provided for each plasma sample, as is used in clinical laboratories for the diagnosis and long-term monitoring of
glucose control in diabetic patients. 31-35
Figure 1 shows the general procedure that was used to isolate HSA and in vivo glycated HSA from serum or plasma samples. This procedure was conducted by using a 20 μL serum or
plasma sample. In this study, such a sample was used as a representative portion of 1–2 mL of remnant EDTA plasma that
was acquired for an individual patient; in future work, finger
stick samples might also be employed, as are commonly used
in routine glucose monitoring. The 20 μL of serum or plasma
was added to a Vivaspin 6 spin-filter column that contained a
fresh 400 μL portion of a 50% packed resin slurry with polyclonal anti-HSA antibody fragments immobilized onto crosslinked agarose beads. Further details on the procedure for this
isolation step, including the sample loading and elution conditions, are provided in the Supporting Information and Results
and Discussion.
Nucleosil Si-300 silica was converted into a diol-bonded
form. 36 One portion of this support was used to immobilize HSA/glycated HSA by the Schiff base method, 37 while a
second portion was used to make a control support to which

Figure 1. Scheme for the purification of human serum albumin (HSA) and in vivo glycated HSA from serum or plasma,
as used prior to the immobilization of these proteins in affinity microcolumns. More details are provided in the Supporting Information.

Affinity Microcolumns

for

Drug–Protein Binding Studies

no protein was added during the immobilization step. Each
HSA/glycated HSA support and control support was downward slurry-packed at 24 MPa (3500 psi) into a separate 2.0
cm × 2.1 mm I.D. stainless steel column using pH 7.4, 0.067 M
potassium phosphate buffer as the packing solution and was
stored in this buffer at 4 °C when not in use. A BCA assay was
performed to determine the protein content of each support,
using normal HSA or in vitro glycated HSA as the standard
and the control support as the blank. 25, 38
Chromatographic Studies. All chromatographic experiments were conducted at 37 °C and using pH 7.4, 0.067
M potassium phosphate buffer as the mobile phase. All drug
and solute solutions were prepared in this mobile phase and
filtered through a 0.2 μm nylon filter, followed by a 15 min degassing step, prior to use. The solutions and samples of the
sulfonylurea drugs and R-warfarin were used within two weeks
of preparation. 24-27, 39, 40 The l-tryptophan solutions were prepared fresh daily in the pH 7.4 buffer. 40 The samples were applied or injected at a typical flow rate of 0.5 mL/min, as shown
in prior work to give reproducible retention factors and binding capacities for these drugs and solutes on similar HSA columns. 24-27, 39, 40
In the frontal analysis studies, each column was first equilibrated with the pH 7.4 mobile phase buffer. The mobile phase
was then switched to a solution that contained a known concentration of the desired drug in the same buffer. These solutions included up to sixteen concentrations of acetohexamide
that ranged from 1 to 1000 μM and ten concentrations of gliclazide or tolbutamide that ranged from 1 to 200 μM. These
conditions included the typical therapeutic levels for these
drugs and provided a sufficiently broad range of conditions to
allow the observation of both weak and moderate-to-high affinity interactions of these solutes with glycated HSA. 24-27, 41
Each drug solution was continuously applied to the column
until a breakthrough curve with a level plateau was produced.
The system was later switched back to the pH 7.4, 0.067 M
phosphate buffer to elute the retained analyte from the column
under isocratic conditions. This process was repeated three
times at each concentration for all drugs on the test columns
and control column.
To keep the absorbance values within the linear range of
the detector, the breakthrough curves for acetohexamide were
monitored at 248 nm for concentrations of 1–20 μM and at 315
nm for concentrations of 30–1000 μM. Gliclazide and tolbutamide were monitored at 248 nm for all of the concentrations
used in frontal analysis. The central location of each breakthrough curve was determined by using a Savitzky-Golay first
derivative algorithm for smoothing, followed by fitting of the
first derivative to an exponentially modified Gaussian curve.
A correction for any nonspecific binding of a drug to the support was made by subtracting the breakthrough times of the
control column from those obtained on the test column at each
drug concentration, as described previously for the same analytes on columns based on normal HSA or in vitro glycated
HSA. 24-27, 39, 40
Zonal elution studies were performed by using R-warfarin
and l-tryptophan as site-specific probes for Sudlow sites I and
II of HSA. 24-27, 39, 40 The pH 7.4 mobile phase was used to prepare all of the injected samples and competing agents for these
experiments. The acetohexamide, gliclazide, or tolbutamide
solutions ranged in concentration from 0 to 20 μM. The samples consisted of 20 μL injections of 5 μM R-warfarin or 5 μM
l-tryptophan that were prepared by diluting each probe with a
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mobile phase that contained the final desired concentration of
the competing agent. Elution of the injected solutes was monitored at 308 nm for R-warfarin and at 280 nm for l-tryptophan. Nonspecific binding was evaluated and corrected by injecting all of the samples onto a control column. To determine
the void time of each column, 20 μL injections of 20 μM sodium nitrate were made (i.e., a nonretained solute on HSA columns), and the resulting peak was monitored at 205 nm. The
central moment of each peak was determined by using a fit to
an exponentially modified Gaussian curve. 39

Results and Discussion

Isolation of HSA and Glycated HSA. Immunoextraction based on polyclonal anti-HSA antibodies was used to
isolate HSA and glycated HSA from serum or EDTA plasma.
This was conducted by using a commercial anti-HSA support with a binding capacity of at least 2 mg of HSA/mL resin.
The extraction efficiency of this approach was tested by combining a fresh 400 μL portion of the immunoaffinity support
with a 20 μL standard sample that contained 800 μg of HSA or
40 g/L HSA (i.e., a representative concentration for this protein in serum or plasma). 41 This sample was applied to the
support in pH 7.4, 0.10 M Tris buffer, which was also added
in a 200 μL portion to wash away nonretained sample components. Two 200 μL portions of pH 2.8, 0.10 M glycine–HCl
buffer were then added to elute the retained protein, as recommended by the manufacturer. A fresh portion of the immunoaffinity resin was then used for the next sample application,
thus avoiding the need for column regeneration and providing
stable antibodies with a high and consistent level of binding.
However, regeneration and reuse of such a resin could also
have been employed, as has been described for other anti-HSA
columns. 42, 43
Only 54% of the applied HSA was recovered by the initial immunoextraction approach, in agreement with prior observations made under similar conditions with the same type
of anti-HSA resin. 44 As the number of elution steps was increased from two to six, the recovery of HSA increased to 90%.
A recovery of at least 90% and approaching 100% was also
noted when this study was repeated for samples that contained
highly glycated HSA that was previously prepared in vitro with
a level of modification of 3.35 (±0.14) mol hexose/mol protein. 25 A high level of recovery was not essential to the binding studies that were later carried out with the final affinity
microcolumns, as long as a representative portion of the original protein population had been captured; however, a high recovery did reduce the sample volume that was needed to prepare the affinity microcolumns. The specificity of the modified
purification approach was examined by using it with a 20 μL
commercial sample of human serum known to contain 1020
μg protein and 840 μg HSA. The retained and isolated protein
fraction showed only one detectable band by SDS-PAGE which
matched that of an HSA standard, in agreement with previous
work using this support. 44-46
A number of buffer combinations were tested with the immunoextraction method to obtain a high recovery for HSA and
glycated HSA while avoiding long-term changes in the activities of these proteins. In these experiments, 20 μL of 40 mg/
mL HSA or highly glycated HSA was incubated at room temperature for 20 min with 200 μL of 0.10 M glycine-HCl buffer that had a pH of 2.8 to 4.0. This incubation step was followed by neutralization of the solution to a pH of 7.0–7.4 by
adding 10 μL of pH 8.0, 1.0 M Tris buffer. A binding study
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based on ultrafiltration, as described in the Supporting Information and using tolbutamide, was then carried out with (1)
the treated protein samples and (2) control samples that had
the same final concentrations of drug and HSA/glycated HSA
but that were placed directly into pH 7.4, 0.10 M Tris buffer. In
each case, the controls and treated samples had no significant
difference in their binding at the 95% confidence level. The effect of the elution pH on protein recovery was also considered.
A decrease in the recovery of HSA from over 90% to 25% was
observed when increasing the elution pH from 2.8 to 3.5. On
the basis of these results, an approach using an elution pH of
2.8 was used in all later experiments involving immunoextraction for the isolation of in vivo glycated HSA.
Preparation of Affinity Microcolumns Using
Clinical Samples. The scheme optimized in the previous
section was next used to isolate glycated HSA from individual clinical samples. This was of interest because recent studies have found that there are differences in the binding of sulfonylurea drugs to samples of normal HSA, as prepared from
pooled serum, versus in vitro glycated HSA that has various
levels of glycation. 24-27 However, it is not yet known whether
changes with glycation also occur for these drugs with HSA
that has been glycated in vivo. Also, no known previous studies have examined the creation of affinity columns for binding
studies that have used HSA or other proteins from specific individuals. 28, 29 Work in this section sought to develop tools for
obtaining such information by creating affinity microcolumns
that were prepared by using in vivo glycated HSA from individual patients.
To explore this approach, microcolumns were prepared using two different preparations of in vivo glycated HSA. The
first clinical sample, glycated HSA-CS1, was from a diabetic
patient who had an HbA1c level of 10.0%, which represented
an estimated long-term glucose level of 15.5 mM in blood 47
(Note: An HbA1c value of ≥6.5% is often used to indicate the
presence of diabetes in a patient). 33-35 The second sample, glycated HSA-CS2, came from a patient who had an HbA1c level
of 13.7%, which represented a case of uncontrolled and/or advanced diabetes and an estimated long-term glucose level of
22.8 mM. 47 The measured levels of glycation were 1.19 (±0.15)
and 1.51 (±0.20) mol hexose/mol HSA for the isolated samples of HSA-CS1 and HSA-CS2. The results obtained for these
columns were also compared to those obtained previously for
normal HSA that was obtained from pooled human serum. 24
The column size that was used with these samples was 2.0
cm × 2.1 mm I.D. It was known from previous work with normal HSA that this size was suitable for use in drug binding
studies and offered good precision along with reasonably fast
analysis times. It was also known from prior work that a column of this size could contain roughly 1 mg of immobilized
HSA when using the same type of silica as employed in this report. 24 This amount of HSA corresponded to what is found in
approximately 20–28 μL of human serum or plasma. 41 When
the isolated in vivo glycated HSA was immobilized by the
Schiff base method, the final supports contained 26 (±1) mg
protein/g silica for glycated HSA-CS1 and 14 (±1) mg protein/g
silica for glycated HSA-CS2. These results represented a total
protein content of 0.4–0.8 mg or 6–12 nmol (3.6–7.2 × 1015
molecules) in the 2.0 cm × 2.1 mm I.D. columns. Previous
work with in vitro glycated HSA and the same column size has
found good agreement with binding parameters that have been
obtained using much larger amounts of protein in ultrafiltra-
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tion studies, 25, 27 indicating that the amount of protein in these
microcolumns was sufficient to provide a good representation
of the glycated HSA populations and their binding properties
in the original clinical samples.
Frontal Analysis Studies for Clinical Samples.
The columns containing in vivo glycated HSA were examined
by frontal analysis to study their overall binding to various sulfonylurea drugs. Each frontal analysis experiment took roughly
6–8 min to complete at 0.5 mL/min on a 2.0 cm × 2.1 mm I.D.
microcolumn (see Supporting Information for examples). This
meant that even triplicate experiments over a wide range of
concentrations could be carried out in a reasonable amount of
time. Each of the in vivo glycated HSA columns was used over
the course of approximately 9–12 months and at least 250 sample application cycles for the work described in this report.
The stability of these columns was monitored by examining
their retention for R-warfarin and l-tryptophan, as determined
through the site-specific competitive studies that are described
later for these same columns. During the entire period of this
study, the maximum variation in the retention factor for Rwarfarin was 13–31%, and the maximum variation in the retention factor for l-tryptophan was 3–22%; changes of less than
5–11% and 1–3%, respectively, were noted in these same parameters over the first 2–3 months of column operation. This
level of variation did not create any problems during the analysis of data from the frontal analysis experiments, as illustrated
by Figure 2 and Equation 1, which provided association equilibrium constants that were determined independently from the
column binding capacity. 28 This feature also meant it was not
necessary to capture all of the glycated HSA/HSA from a sample or to have the same amount of protein in each microcolumn
for these measurements, as long as a representative portion of
the original protein population was present.

Figure 2. Fit of frontal analysis data obtained for acetohexamide on the glycated HSA-CS1 column when using a twosite binding model, as described by Equation 1. 25 Each data
point represents the average of three measurements for
mLapp, the moles of analyte required to reach the mean point
of the breakthrough curve at a given molar concentration
of the applied analyte. The error bars represent ±1 SD for
this value and ranged in size from ±0.01–5.5% (average, ±
1.1%). Terms: molar concentration of applied analyte A, [A];
Ka1 and Ka2, association equilibrium constants for the analyte
at binding sites 1 and 2; mL1 and mL2, total moles of binding
sites 1 and 2 in the column.
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for

Drug–Protein Binding Studies
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Table 1. Binding Parameters Obtained by Frontal Analysis and Using a Two-Site Model to Describe the Interactions of Various Sulfonylurea Drugs with Columns Containing Normal HSA or in vivo Glycated HSAa
 	

high affinity sites
Ka1(×105

M–1)

mL1(×10–8

column/drug
			

M–1)

lower affinity sites
Ka2(×103

relative activity
M–1)
mL2(×10–8 M–1)
(mol/mol HSA) 			

relative activity
(mol/mol HSA)

tolbutamide
gliclazide
acetohexamide

0.87 (±0.06)
0.71 (±0.19)
1.3 (±0.2)

2.0 (±0.1)
0.71 (±0.22)
2.4 (±0.1)

normal HSAb
1.12 (±0.08)
0.50 (±0.16)
1.3 (±0.1)

8.1 (±1.7)
8.9 (±1.5)
0.35 (±0.30)

1.8 (±0.1)
2.7 (±0.1)
9.3 (±5.5)

1.01 (±0.08)
1.9 (±0.2)
5.2 (±3.1)

tolbutamidec
gliclazide
acetohexamide

0.97 (±0.12)
0.65 (±0.25)
1.0 (±0.1)

1.2 (±0.2)
0.55 (±0.27)
1.6 (±0.1)

glycated HSA-CS1
0.96 (±0.22)
0.45 (±0.22)
1.3 (±0.1)

5.7 (±2.2)
11 (±3.0)
1.2 (±0.9)

1.2 (±0.3)
1.6 (±0.2)
1.7 (±0.5)

1.0 (±0.2)
1.3 (±0.2)
1.4 (±0.4)

tolbutamide
gliclazide
acetohexamide

0.91 (±0.19)
0.77 (±0.13)
1.4 (±0.1)

0.80 (±0.17)
0.38 (±0.06)
0.86 (±0.03)

glycated HSA-CS2
1.2 (±0.25)
0.56 (±0.09)
1.3 (±0.1)

10 (±5)
5.0 (±0.9)
1.0 (±0.3)

0.71 (±0.16)
1.4 (±0.1)
2.2 (±0.3)

1.04 (±0.17)
2.08 (±0.09)
3.2 (±0.5)

a. All of these data were obtained at pH 7.4 and 37 °C. The values in parentheses represent a range of ±1 SD, as obtained through nonlinear regression for the best-fit parameters to Equation 1 to the group of results (n = 10–16, each measured in triplicate) or through error propagation
based on the standard deviations for these parameters.
b. The values provided for acetohexamide or tolbutamide and gliclazide with normal HSA are given for reference and were also measured by
HPAC. These results were obtained from References 24 and 27.
c. The Ka1 and mL1 values for tolbutamide with glycated HSA-CS1 were estimated from the linear region of a double reciprocal plot made according to Reference 24.

The frontal analysis data were analyzed by preparing a
graph of the moles of applied analyte that were required to
reach the central point of the breakthrough curve versus the
concentration of analyte that was applied to the column. An
example of such a plot is shown in Figure 2. These data were
fit to various binding models. The results for acetohexamide in
Figure 2 had the best-fit to the two-site model in Equation 1,
with a correlation coefficient of 0.993 (n = 16) and only random variations in the corresponding residual plot. Fitting the
same data to a one-site model (see Supporting Information)
gave a lower correlation coefficient of 0.967 and nonrandom
variations in a residual plot. No further improvement in the fit
was obtained when using a three-site model. Similar results
were obtained for acetohexamide on the glycated HSA-CS2
column and for tolbutamide and gliclazide with both microcolumns containing in vivo glycated HSA (i.e., correlation coefficients of 0.999 for the two-site model versus 0.949–0.997 for
the one-site model at n = 10–16). The best fit noted to a twosite binding model is consistent with previous results reported
for the same drugs on columns that contained normal HSA or
in vitro glycated HSA. 24-27 Table 1 summarizes the equilibrium
constants and moles of binding sites that were estimated with
the two-site model for the sulfonylurea drugs on the in vivo
glycated HSA columns. Previous values obtained for normal
HSA are also provided for reference. 24, 27
The two classes of sites taking part in these interactions
consisted of relatively high affinity interactions involving 1–2
binding regions (i.e., as estimated based on the specific activities in Table 1) and a group of lower affinity sites involving
up to 3–5 regions on HSA. These results were consistent with
those reported for the same drugs with normal HSA or in vitro glycated HSA. 24-27 The apparent association equilibrium
constants that were estimated for the group of high affinity regions had relative standard deviations of ±7.1 to ±38% (average, ± 18%) and were in the general range of 0.65–1.4 × 105
M–1. This range was consistent with earlier values reported
for the same drugs with in vitro glycated HSA that had similar or slightly lower levels of glycation (i.e., binding constants

of 0.84–1.2 × 105 M–1 for tolbutamide, 1.0 × 105 M–1 for gliclazide, and 1.2–2.0 × 105 M–1 for acetohexamide). 25-27
Site-Specific Competition Studies for Clinical
Samples. The next set of studies used zonal elution and competition studies with site-specific probe compounds to explore
the high affinity regions on in vivo glycated HSA that were interacting with the sulfonylurea drugs. A representative set of chromatograms for these studies is provided in the Supporting Information. These experiments typically required 4–7 min per run,
which again made it easy to employ the microcolumns for replicate studies with various drugs and experimental conditions. As
noted earlier, the in vivo glycated HSA columns had good stability and showed only relatively small changes in their retention
factors for R-warfarin and l-tryptophan during the course of
these studies. In addition, the approach that was used to analyze
the zonal elution data, as illustrated in Figure 3 and Equation
2, provided association equilibrium constants that were determined in a manner that was independent of any modest variations that occurred in the column binding capacity. 28 This fact
again meant that only a representative portion of the glycated
HSA/HSA from a sample was needed for this type of study and
that this method could be used even when there were moderate differences in the amounts of protein in the affinity microcolumns that were prepared from different samples.
Competition studies at Sudlow site I were conducted by using R-warfarin as a site-specific probe. 20, 24, 28, 29 Figure 3a
gives examples of the resulting plots of 1/k versus the mobile
phase concentration of the tested drug, as prepared according
to Equation 2. These plots gave linear relationships for all of
the sulfonylurea drugs and in vivo glycated HSA columns, with
correlation coefficients of 0.951–0.990 (n = 6–7) and only
random variations in the data points about the best-fit lines.
These results were consistent with a model in which the sulfonylurea drugs had binding and direct competition with R-warfarin at Sudlow site I. Similar behavior has been noted for columns containing normal HSA or in vitro glycated HSA. 24-27
The best-fit lines for plots like those in Figure 3a were
used to obtain the association equilibrium constant for each
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Table 2. Association Equilibrium Constants (KaI) Measured
at Sudlow Sites I and II for Various Sulfonylurea Drug with
Normal HSA and in Vivo Glycated HSA
binding site 	
and column

KaI(×104 M–1)a
tolbutamide

gliclazide

acetohexamide

Sudlow site I
normal HSAb
5.5 (±0.2)
1.9 (±0.04)
glycated HSA-CS1 6.8 (±0.5)
2.3 (±0.2)
glycated HSA-CS2 7.9 (±0.4)
1.4 (±0.1)

4.2 (±0.4)
4.7 (±0.3)
4.0 (±0.4)

Sudlow site II
normal HSAb
5.3 (±0.2)
6.0 (±0.5)
glycated HSA-CS1 7.3 (±0.5)
11 (±1.0)
glycated HSA-CS2 7.9 (±0.3)
9.2 (±0.7)

13 (±1.0)
13 (±0.2)
17 (±0.4)

a. These binding parameters were calculated from data obtained at
pH 7.4 and 37 °C using the best-fit lines generated according Equation 2. The values in parentheses represent a range of ±1 SD for
the population of results (n = 6–7, each measured in triplicate) and
were determined by using error propagation with the standard deviations of the slopes and intercepts of the best-fit lines that were obtained when using Equation 2.
b. The values provided for acetohexamide or tolbutamide and gliclazide with normal HSA were obtained from References 24 and 27.

Figure 3. Change in the retention factor (k) at (a) Sudlow
site I for R-warfarin in the presence of tolbutamide as a competing agent and (b) at Sudlow site II for l-tryptophan in the
presence of acetohexamide, as obtained for columns containing glycated HSA-CS1 (●) or glycated HSA-CS2 (■). The error bars represent ±1 SD for three replicate measurements
of 1/k and are often comparable in size to the markers used
in these plots, especially in (a). The size of these error bars
ranged from (a) ± 0.08–0.93% (average, ± 0.24%) to (b) ±
0.60–5.0% (average, ± 1.9%). Equation 2 represents the relationship that is expected for a system with direct competition at a single type of binding site between the retention factor for the injected probe (A) and the molar concentration of
the competing agent in the mobile phase, [I]. Terms: KaA and
KaI, association equilibrium constants for the injected probe
and competing agent, respectively, at their site of competition; VM, column void volume; mL, moles of common binding sites for A and I. On the basis of Equation 2, a plot of 1/k
versus [I] should produce a linear relationship for a system
with single-site competition, where the value of KaI can be
found by taking the ratio of the slope over the intercept. 25.

sulfonylurea drug at Sudlow site I on the samples of in vivo
glycated HSA (see Table 2), giving values that had relative
standard deviations ranging from ±5.1 to ±10.0% (average, ±
7.4%). These equilibrium constants were in the range expected
for one of the high affinity regions of these drugs on HSA and
showed good agreement with previous values of 6.5–6.9 × 104
M–1 for tolbutamide, 1.8–3.6 × 104 M–1 for gliclazide, and 3.8–
5.9 × 104 M–1 for acetohexamide that have been measured at
the same site when using in vitro glycated HSA with similar or
slightly lower levels of glycation. 25-27
As has been noted in prior work with in vitro glycated
HSA, 25-27 the strength of these interactions and the change in
these interactions with the extent of glycation differed between
the drugs that were tested. For instance, the association equilibrium constant for tolbutamide at Sudlow site I increased by 1.2to 1.4-fold in going from normal HSA to both samples of in vivo
glycated HSA. These shifts in affinity, as well as the 1.2-fold increase in binding strength seen for tolbutamide in going from
glycated HSA-CS1 to glycated HSA-CS2, were all significant at

the 95% confidence level. (Note: The same confidence level was
used in all further comparisons in this study.) For gliclazide,
an increase of 1.2-fold or a decrease of 0.74-fold in affinity occurred when comparing normal HSA with glycated HSA-CS1 or
glycated HSA-CS2. A small increase of 1.1-fold or a decrease of
0.95-fold in affinity may have been present for acetohexamide
in going from normal HSA to glycated HSA-CS1 or glycated
HSA-CS2, but these differences were not statistically significant.
In addition, a 0.61-fold decrease in affinity was noted for gliclazide between glycated HSA-CS1 and glycated HSA-CS2.
It has been suggested that changes in binding like those
seen in Table 2 may be produced by variations in the extent
and types of modifications that occur at various regions on
HSA during the glycation process. 16, 18, 25-27 This is supported
by the fact that such modifications have been previously noted
to occur at or near Sudlow sites I and II for both in vivo glycated HSA and in vitro glycated HSA, 48-50 with the latter being
prepared under the same or similar conditions to those used
for the binding studies in refs 25−27. The shifts in binding seen
in Table 2 are consistent with the fact that glycation-related
modifications at Sudlow sites I and II have also been found for
samples of the in vivo glycated HSA that were used in this current study (see Supporting Information). In addition, it has
been observed with in vitro glycated HSA that the pattern of
these modifications can vary with the level of glycation. 48, 49
This explains why the affinity for a drug at individual binding
sites may change between normal HSA and glycated HSA or
between two different preparations of glycated HSA, 25-27 as is
illustrated in Table 2.
Additional competition studies were carried out by using
l-tryptophan as a probe for Sudlow site II, 20, 24, 28, 29 as illustrated in Figure 3b. Plots prepared according to Equation 2
gave linear behavior for all the sulfonylureas tested, indicating that these drugs had binding and direct competition with
l-tryptophan at Sudlow site II. The correlation coefficients for
these graphs ranged from 0.975 to 0.999 (n = 6–7) and gave
only random variations in the data points about the best-fit
lines. These results agreed with data that have been obtained
for the same drugs using columns that contained normal HSA
or in vitro glycated HSA. 24-27

Affinity Microcolumns

for

Drug–Protein Binding Studies

Table 2 shows the association equilibrium constants at Sudlow site II that were calculated from plots like those in Figure
3b. These values had relative standard deviations ranging from
±1.5 to ±9.1% (average, ± 5.2%). These equilibrium constants
were in the range expected for one of the high affinity regions
on glycated HSA and were similar to values of 5.9–7.2 × 104
M–1 for tolbutamide, 3.8–7.6 × 104 M–1 for gliclazide and 7.9–
12 × 104 M–1 for acetohexamide that have been measured previously at Sudlow site II with in vitro glycated HSA that had
similar or lower levels of glycation. 25-27 In this current study,
tolbutamide had a 1.4- to 1.5-fold increase in affinity at Sudlow site II in going from normal HSA to glycated HSA-CS1 or
glycated HSA-CS2. For gliclazide, an increase of 1.8- or 1.5fold was seen at the same binding region in going from normal
HSA to glycated HSA-CS1 or glycated HSA-CS2, respectively.
No apparent change was seen when comparing the binding
of acetohexamide at this site on normal HSA versus glycated
HSA-CS1; however, a 1.3-fold increase in affinity was noted
when the binding of acetohexamide at Sudlow site II on either
of these columns was compared with the affinity noted for glycated HSA-CS2.

Conclusion

It was found that affinity microcolumns could be used as
analytical tools to examine the binding of drugs to modified
proteins from individual clinical samples. This approach was
demonstrated by using it to investigate the binding of several
sulfonylurea drugs to in vivo glycated HSA. Only 20 μL of serum or plasma was needed to prepare each affinity microcolumn, which contained 6–12 nmol protein. These microcolumns could be used to conduct binding studies with typical
run times of 4–8 min and were quite stable, making it possible
to obtain good reproducibility and to reuse the same protein
preparation for many studies. For instance, over the course of
more than 250 sample application cycles on each microcolumn, the equivalent of only 25–50 pmol protein was needed
per experiment.
These affinity microcolumns were utilized in several formats to examine the binding of sulfonylurea drugs with in
vivo glycated HSA that was obtained from individual patients. Frontal analysis was employed to investigate the overall binding of each sulfonylurea drug and indicated that these
drugs gave the best-fit to a model involving a group of 1–2
high affinity sites and a group of up to 3–5 lower affinity
binding regions. The apparent association equilibrium constants measured for the high affinity sites of the in vivo glycated HSA were in the general range of 0.65–1.4 × 105 M–1,
which agreed with values that have been reported for the
same drugs with comparable preparations of in vitro glycated
HSA. 25-27
Zonal elution was utilized to study the interactions that occurred at specific binding sites on HSA. These experiments indicated that both Sudlow sites I and II on the in vivo glycated
HSA were binding to all of the tested drugs. The association
equilibrium constants for these interactions were consistent
with values expected for the high affinity sites of these drugs.
These values also agreed with previous data obtained for these
drugs at the same sites on in vitro glycated HSA with similar
levels of modification. 25-27 All of these results confirmed that
the in vivo glycated HSA columns could be used to study the
binding of drugs to modified proteins in a disease, such as diabetes, and in comparing samples from separate patients. It
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was further possible to use the data from these columns to see
how these interactions changed with the extent of glycation. In
some cases, the change in affinity at a given site was as large
as 1.8-fold in going from normal HSA to in vivo glycated HSA.
This observation also agrees with previous results for the same
drugs and similar preparations of in vitro glycated HSA, for
which changes in affinity of up to 1.4- to 1.9-fold have been reported. 25-27 It is possible that even larger shifts in binding may
be observed in future work when this approach is applied to a
larger number of clinical samples. These changes are of possible clinical importance in that they would be expected to alter the displacement of these drugs by other agents and the
amount of such a drug that is present in the nonbound protein
form in serum or plasma. These effects, in turn, could change
the effective dose of the drug in a patient and lead to undesirable effects such as hypoglycemia or poor control of glucose
levels. 22, 23, 25-27
The methods that were described in this study for preparing and using affinity microcolumns in binding studies are
not limited to individual clinical samples of glycated HSA but
could be adapted for work with alternative proteins or modified proteins. Examples of other serum carrier proteins that
should be amenable to this approach include α1-acid glycoprotein and lipoproteins, both of which have been used in
prior drug-binding studies by HPAC involving proteins prepared from pooled serum 51-55 and which are known to vary in
their composition or structure with disease state. 56-58 It is expected that the application of this method could also be expanded to include proteins that have been modified through
processes other than glycation (e.g., glycosylation or alterations because of oxidative stress). 56-58 In the future, this
method could be extended to systems such as cytosolic proteins that bind to lipids, hormones, or drugs. 59-61 The main
requirement in each of these cases is the use of an appropriate immunoaffinity support or comparable protein isolation
system, and a sufficient sample volume to isolate the desired
protein for placement in an affinity microcolumn. Continued
improvements in the design of affinity microcolumns, along
with the development of better isolation and immobilization
schemes for work with small amounts of proteins, should
further assist in this research. The expected result is a set of
powerful tools for binding studies that will be applicable for
use in personalized medicine and in the study of various disease states, ranging from diabetes to cancer and autoimmune
disorders. 56-61

Supporting Information. Additional material as described in the body of the paper is available following the
References.
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Supporting Information
Sample collection and pretreatment. The initial clinical samples were collected
according to standard protocols by venipuncture for the analysis of hemoglobin A1C
(HbA1C) using a 5 mL EDTA plasma collection tube. The anticoagulated whole blood
was processed to give plasma by using centrifugation at 2000 × g for 10 min to separate
the plasma from the cells. After centrifugation, the plasma was removed from the tube.
A 1-2 mL portion of de-identified and remnant EDTA plasma was set aside and frozen at
–20ºC until shipment. The frozen specimens were placed on dry ice during shipping and
were stored at -80ºC upon receipt and until further use.
To isolate HSA and in vivo glycated HSA from plasma or control serum, 20 L of
a plasma or serum sample was added to a Vivaspin 6 spin-filter column that contained a
fresh 400 L portion of a 50% packed resin slurry with polyclonal anti-HSA antibody
fragments immobilized onto cross-linked agarose beads. The initial buffer in this slurry
was given by the manufacturer as being a proprietary pH 7.0-7.5 Tris buffer with a low
salt concentration. The antibody-containing beads had a reported minimum binding
capacity of 2 mg HSA/mL resin. The sample/resin mixture was placed on a rotary shaker
for 15 min at room temperature. After this incubation step, the spin-filter column was
centrifuged at 400
1 min at 400

g for 2 min and washed with 200 L of pH 7.4, 0.1 M Tris buffer for

g. This washing procedure was repeated two times to reduce non-specific

binding of sample components to the resin. To elute the retained HSA and glycated
HSA, the spin-filter column was washed six times with 200
glycine/HCl buffer for 2 min at 400

L of pH 2.8, 0.1 M

g, with the collected HSA/glycated HSA fractions

being pooled. Immediately after each elution step, the collected fractions were adjusted

to approximately pH 7.0 by adding pH 8.0, 1 M Tris buffer. If additional HSA/glycated
HSA was needed for other experiments (e.g., protein assays or mass spectrometry, as
used in ongoing studies), this process was repeated for several cycles, each with a fresh
spin-filter column, and the isolated proteins were pooled prior to use or further analysis.
The collected HSA/glycated HSA for a given sample was placed into a sterile
Slide-A-Lyzer dialysis cassette (10 kDa MW cutoff; 0.1–0.5 mL sample volume from
Thermo Scientific, Rockford, IL) and dialyzed twice against two portions of 2.5 L water
with gentle stirring for 2 h at room temperature. The sample was dialyzed against water a
third time without stirring at 4°C for 14–18 h, with the protein then being lyophilized and
stored at -80°C for later use in immobilization or analysis (Note: An alternative
procedure that can be used is to dialyze the sample against an appropriate buffer and then
use the soluble protein directly for immobilization). To determine if these isolation steps
affected the activity of HSA, binding studies based on ultrafiltration, as described later in
this section, were performed before and after representative samples of the control HSA
and glycated HSA were treated with the low pH buffer, dialyzed and lyophilized. It was
found that this process gave no significant changes, at the 95% confidence level, in the
binding of HSA with the sulfonylurea drugs that were examined in this study.
Ultrafiltration

studies.

Ultrafiltration

was

performed

using

Centrifree

micropartition devices (30 kDa MW cutoff, 0.15–1.0 mL sample capacity) from Amicon
(Danvers, MA, USA). These devices were used along with a 5702RH temperaturecontrolled centrifuge from Eppendorf (New York, NY) and a fixed-angle centrifuge rotor
from VWR (West Chester, PA). The flow-injection analysis experiments that were used
to measure the drug content in each filtrate were carried out by using a Jasco 2000 HPLC

system (Easton, MD, USA) that contained a DG-2080-53 three solvent degasser, two PU2080 isocratic pumps, an AS-2057 autosampler equipped with a 100

L sample loop

(operated in the partial loop injection mode), and a UV-2075 absorbance detector.
For the ultrafiltration-based binding studies, each mixture of tolbutamide and
HSA or glycated HSA was incubated at 37ºC for 45 min; the use of longer incubation
times (i.e., up to 90 min) did not produce any significant change in the final results. Prior
to ultrafiltration, the membrane in each Centrifree ultrafiltration device was rinsed three
times with water and pH 7.4, 0.067 M potassium phosphate buffer to reduce interferences
by any contaminants or preservatives that may have been present in the device. The
ultrafiltration device was spun for at least 15 min at 1,500

g after rinsing to avoid

dilution errors due to the presence of any remaining rinse solution in the device; the
volume of rinse solution that remained after this step was less than

10

L.

The

ultrafiltration experiments were carried out by placing 1 mL of each drug/protein mixture
into the ultrafiltration device and spinning this mixture at 1,500

g for 25 min at 37 ºC.

The filtrate was collected and analyzed for its drug content by making triplicate 5 L
injections onto a flow-injection analysis system at 0.5 mL/min and in the presence of pH
7.4, 0.067 M potassium phosphate buffer. The elution of tolbutamide was monitored at
227 nm. A correction for any contaminants or preservatives remaining in the filtrate was
made by carrying out similar measurements on filtrates for 0.5 mL samples that contained
only glycated HSA in pH 7.4, 0.067 M potassium phosphate buffer.
Notes on other experimental methods. In the bicinchoninic acid (BCA) protein
assay that was performed to determine the protein content of each HSA/glycated HSA
support, there was no measureable difference in the response for standards based on

normal HSA versus glycated HSA in this assay. Although sulfonylurea drugs are weak
acids with pKa values of 5.2-6.2, a change in pH of less than 0.05 units was seen in the
pH 7.4 buffer when these drugs were present even at the highest concentrations that were
utilized in the frontal analysis and zonal elution experiments.
In the frontal analysis studies shown in Figure 2, the relative standard deviations
for the measured binding capacities ranged from only

0.01% to

5.5% (average,

1.1%) for triplicate measurements at the sixteen tested drug concentrations. Similar
precisions were obtained for the other columns and drugs that were examined in this
study. The zonal elution results in Figure 3(a-b) gave retention factors with relative
standard deviations that ranged from
0.60% to

5.0% (average,

0.08% to

0.93% (average,

0.24%) and

1.9%) for triplicate injections of R-warfarin or L-tryptophan

as the injected probe, respectively, and over seven concentrations of tolbutamide or
acetohexamide in the mobile phase for the in vivo glycated HSA columns. Similar
precisions were again obtained with the other drugs that were examined.
Analysis of glycation products and glycation patterns. Both qualitative and
quantitative studies based on MALDI–TOF-MS were used to examine the types and
levels of modification that occurred for the in vivo glycated HSA, as based on methods
described in Refs. 1s-4s. The results are summarized in Tables 1s and 2s for clinical
sample HSA-CS1. These data include the regions of the in vivo glycated HSA that were
found to be glycated, as well as the suspected residues at which these regions were
modified and the types of modifications which may have been present.
The data in Tables 1s and 2s show that there were several modifications in this
sample of in vivo glycated HSA that occurred at or near Sudlow sites I and II.1s-5s

Regions that were found to be modified and that occurred around these sites included
residues 160-181, 189-208, 196-212, 275-286 and 286-297, all of which were located
within Sudlow Site I. In addition, residues 359-376, 415-436 and 476-500 are located at
or near Sudlow site II and were also found to be modified during in vivo glycation. These
results agree with those seen in this report for the binding studies using the same
preparation of in vivo glycated HSA, in which shifts in affinity were noted for several of
the sulfonylurea drugs at Sudlow sites I and II when comparing this protein preparation to
normal HSA.
Table 1s summarizes the results of quantitative studies that made of use of
MALDI-TOF-MS and

16

O/18O-labeling with the in vivo glycated HSA. In this case,

peptides from residues 5-20, 7-17, 94-106, 275-286 and 286-297, among others, were
found to be modified and have elevated

16

O/18O ratios versus control samples that were

prepared using normal HSA. These regions exhibited considerable overlap with the
regions of modification that were previously seen for in vitro glycated HSA samples that
were prepared under similar conditions and used in the binding studies described in Refs.
25-27 (as cited in the main body of the text).
The glycation products formed on the in vivo glycated HSA were identified by
determining the peptide ions with mass values that were unique to the in vivo glycated
HSA samples.3s,4s The corresponding modifications were then determined by comparing
these masses with a theoretical list of modified peptides that might result from a glycated
HSA digest. When this approach was used, several early and late-stage glycation adducts
were assigned to the in vivo glycated HSA sample, as listed in Table 2s. For this sample,
18 peptides were found to be modified to form a mixture of early glycation products and

AGEs. Seven of those modified peptides were also found to be modified in prior work
that used preparations of in vitro glycated HSA, with another two regions showing
significant areas of overlap. For example, modifications were found in regions 189-208,
275-292, 312-321 and 542-585 for both the in vivo glycated HSA and previouslyexamined samples of in vitro glycated HSA.1s-4s
Two different peptides (K190/K199) were found to be modified on the in vivo
glycated HSA to produce CML and LL (see list of abbreviations and full names for these
products that are provided in Tables 1s and 2s); previous studies using in vitro glycated
HSA with various stages of glycation showed modifications assigned to K199 due to FL
at early stages of glycation and due to Pyr during later stages of glycation.2s,4s These
results corroborate that K199 is prone to both in vivo and in vitro glycation, in agreement
with various reports that have found K199 to be a major glycation site on HSA.1s-4s,6s In
addition, K276 and K281 within residues 275-286 were found to be modified to form two
Pyr or C2-CML+AL in the in vivo glycated HSA. In previous studies using in vitro
samples, K281 was modified to form FL-related modifications such as FL-1H2O/FL2H2O, as well as CEL and/or Pyr.4s This information is consistent with other reports that
have denoted K281 as another major modification site in glycated HSA.3s,6s Within the
region 5-20, two peptides (R10/K12) were found to be modified during in vivo glycation
to produce a FL/G-H1 precursor or CML+3,4-dihydroxy-2-imidazoline.

This same

region was found to be modified to form FL on K12 when using an in vitro glycated HSA
sample in Ref. 4s.
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Table 1s.

Glycation versus control (G/C) indices obtained through 16O/18O- labeling
and MALDI-TOF-MS and indicating the presence of an increase in
glycation-related modifications for in vivo glycated HSA versus normal
HSA as a control1s,2s

Residues (Digest)

Modification
site

Potential adductsa

G/C Indexb

275-286 (Trypsin)

K276/K281

CML & Pyr/Pyr

1.9 (± 0.2)

557-565 (Glu-C)

FL/AFGP &
K564

561-574 (Trypsin)

FL/CML

286-297 (Glu-C)

1.7 (± 0.2)c

K286

AFGP

1.9 (± 0.2)c

K573/K574

FL/CML & FL/FL

1.7 (± 0.2)c

R98

G-H1

2.0 (± 0.1)

274-286 (Trypsin)
566-585 (Glu-C)
561-574 (Trypsin)
94-106 (Lys-C)

FL/G-H1 precursor;
5-20 (Lys-C)
R10/K12
7-17 (Glu-C)

CML/3,4-dihydroxy-

1.3 (± 0.1)d

2-imidazoline

476-500 (Lys-C)
R484/R485

ArgP/MG-H1

1.8 (± 0.1)d

480-492 (Glu-C)

a

Abbreviations: AFGP, 1-alkyl-2-formyl-3,4-glycol-pyrole; ArgP, argpyrimidine; CML,

N -carboxymethyl-lysine; FL, fructosyl-lysine; G-H1, hydroimidazolone derived from
glyoxal, or Nε-(5-hydro-4-imidazolon-2-yl)ornithine; MG-H1, hydroimidazolone derived

from

methylglyoxal,

or

Nε-(5-hydro-5-methyl-4-imidazolon-2-yl)ornithine;

Pyr,

pyrraline.
b

c

The values in parentheses represent ± 1 standard error of the mean.

This result was obtained for the tryptic digest. The result for K286 is the value obtained

for residues 275-286.
d

This result was obtained for the Glu-C digest.

Table 2s.

Suspected modification sites found in various digests of in vivo glycated
HSA

Residues (digest)

Suspected sites (modification)a

275-286 (Trypsin)

K276 & K281 (Pyr+Pyr)
K276 & K281 (C2-CML+AL)

415-436 (Trypsin)

K432 (FL-H2O) & R428 (oxMG-H1)

542-560 (Trypsin)

K545 & K557 (Pyr+AL)

189-208 (Glu-C)

K190 & K199 (CML+LL)

278-292 (Glu-C)

K281 & K286 (AL+AL)

K313 or K317 (CML);
312-321 (Glu-C)

359-376 (Glu-C)

K313 & K317 (FL-2H2O+AFGP)
K372 (FL-1H2O)

K573/K574 (FL-1H2O+C2-CML
566-585 (Glu-C)

or CML+FL-2H2O; FL+FL)

557-565 (Glu-C)

K557, K560 or K564 (FL-1H2O+AFGP)

557-571 (Glu-C)

K560 & K564 (FL+CML)

R10 & K12 (FL+C2-G-H1 or
5-20 (Lys)
CML+3,4-dihydroxy-2-imidazoline)

94-106 (Lys)

R98 (G-H1)

160-181 (Lys)

K162 & K174 or R160 & K162/K174 (Pyr+Pyr; CEL+FL1H2O; FL+MG-H1; CEL+3-DG-H1; CEL+THP)

R160 & K162 (AFGP+MG-H1 or

160-174 (Lys)

FL+3,4-dihydroxy-2-imidazoline)

K199/K205 & R197/R209 (C2-CML+oxMG-H1 or

196-212 (Lys)

G-H1+oxMG-H1)

476-500 (Lys)

a

Abbreviations:

R484 & R485 (ArgP+oxMG-H1)

AFGP,

1-alkyl-2-formyl-3,4-glycol-pyrole;

AL,

allysine;

ArgP,

argpyrimidine; C2-CML, N -carboxymethyl-lysine precursor (C2-imine); C2-G-H1,
precursor for hydroimidazolone derived from glyoxal (C2-imine); CEL, Nε-carboxyethyllysine; 3-DG-H1, hydroimidazolone derived from 3-deoxyglucosone; CML, N carboxymethyl-lysine; FL, fructosyl-lysine; FL-xH2O, dehydrated fructosyl-lysine; GH1, hydroimidazolone derived from glyoxal, or Nε-(5-hydro-4-imidazolon-2-yl)ornithine;
LL, 3-(N'-lysino)-lactic acid; MG-H1, ; oxMG-H1, oxidized Nε-(5-hydro-5-methyl-4imidazolon-2-yl)ornithine; Pyr, pyrraline; THP, tetrahydropyrimidine.

Figure Legends
Figure 1s.

Typical chromatograms obtained at 0.5 mL/min by carrying out frontal
analysis on an affinity microcolumn containing glycated HSA-clinical
sample 2 (glycated HSA-CS2) and using solutions that contained 1.0, 2.5
or 5.0 M acetohexamide (bottom-to-top). Other conditions are given in
the text.

Figure 2s.

Fit of frontal analysis data obtained for acetohexamide on the glycated
HSA-CS1 column when using a one-site model, as described by eq (1s).7s
Each data point represents the average of three measurements for mLapp,
the moles of analyte required to reach the mean point of the breakthrough
curve at a given molar concentration of the applied analyte. The error bars
represent ± 1 S.D. for this value and ranged in size from ± 0.01-5.5%
(average, ± 1.1%). Terms: molar concentration of applied analyte A, [A];
Ka1 and Ka2, association equilibrium constants for the analyte at binding
sites 1 and 2; mL1 and mL2, total moles of binding sites 1 and 2 in the
column.

Figure 3s.

Zonal elution results were generated at 0.5 mL/min on the glycated HSA
clinical sample 1 column (glycated HSA-CS1) by using 5 M R-warfarin
as the injected probe and mobile phases that contained 0, 1, 5, 10, 15 or 20
M acetohexamide (bottom-to-top). Other conditions are given in the text.
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